ARBUTUS BIOPHARMA CORP (ABUS) Stock News

NASDAQ:ABUS - Nasdaq - CA03879J1003 - Common Stock - Currency: USD

3.21 -0.03 (-0.93%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ABUS Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Arbutus Biopharma Corporation

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

a month ago - By: Arbutus Biopharma Corporation

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

2 months ago - By: Zacks Investment Research - Mentions: MRSN

Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates

2 months ago - By: Arbutus Biopharma Corporation

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

2 months ago - By: Arbutus Biopharma Corporation

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

2 months ago - By: Zacks Investment Research - Mentions: EDIT

Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year?

3 months ago - By: Arbutus Biopharma Corporation

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

3 months ago - By: Arbutus Biopharma Corporation

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

3 months ago - By: Zacks Investment Research

Will Arbutus Biopharma (ABUS) Report Negative Q1 Earnings? What You Should Know

3 months ago - By: Arbutus Biopharma Corporation

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

3 months ago - By: Arbutus Biopharma Corporation

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

4 months ago - By: Zacks Investment Research

All You Need to Know About Arbutus (ABUS) Rating Upgrade to Buy

4 months ago - By: Zacks Investment Research - Mentions: AVAH

Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?

4 months ago - By: Zacks Investment Research - Mentions: BMY

Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates

4 months ago - By: Arbutus Biopharma Corporation

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

4 months ago - By: Arbutus Biopharma Corporation

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

5 months ago - By: Arbutus Biopharma Corporation - Mentions: ROIV

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

5 months ago - By: Arbutus Biopharma Corporation

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

5 months ago - By: Arbutus Biopharma Corporation

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

6 months ago - By: Arbutus Biopharma Corporation

Arbutus Provides 2025 Corporate and Financial Update

6 months ago - By: Arbutus Biopharma Corporation

Arbutus Provides 2025 Corporate and Financial Update

8 months ago - By: Whitefort Capital Management, LP

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

8 months ago - By: Arbutus Biopharma Corporation

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

8 months ago - By: Arbutus Biopharma Corporation

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

8 months ago - By: Benzinga - Mentions: NOG AVAV DLB ENR ...

Walmart To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Wednesday

8 months ago - By: Arbutus Biopharma Corporation

Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

8 months ago - By: Arbutus Biopharma Corporation

Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

8 months ago - By: Arbutus Biopharma Corporation

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

8 months ago - By: Barinthus Biotherapeutics - Mentions: BRNS

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

8 months ago - By: Arbutus Biopharma Corporation

Arbutus to Present at Jefferies London Healthcare Conference

8 months ago - By: Arbutus Biopharma Corporation

Arbutus to Present at Jefferies London Healthcare Conference

9 months ago - By: Arbutus Biopharma Corporation

Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update

9 months ago - By: Arbutus Biopharma Corporation

Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update

9 months ago - By: Arbutus Biopharma Corporation

Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

9 months ago - By: Arbutus Biopharma Corporation

Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

9 months ago - By: Arbutus Biopharma Corporation

Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024

9 months ago - By: Arbutus Biopharma Corporation

Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024

10 months ago - By: Benzinga - Mentions: ALNY MRNA

Alnylam's Concedes Its Patent Infringement Case Against Moderna's COVID-19 Vaccine